MDS 2023 | Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis

Klaus Metzeler, MD, University of Leipzig Medical Center, Leipzig, Germany, discusses challenges associated with distinguishing between patients with pre-MDS states, such as clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS), and myelodysplastic syndromes (MDS). Dr Metzeler explains that the morphological differences in dysplasia can be subtle between these conditions, and that the subjectivity of these evaluations could elicit different diagnoses from independent practitioners. To overcome this gray area in diagnosis, Dr Metzeler suggests integrating additional diagnostic criteria, such as next-generation flow cytometric measures, and incorporating AI-based approaches. Dr Metzeler further suggests diagnosing and treating these conditions on a continuum based on clinical manifestation rather than strict classification borders. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.